Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of fesoterodine fumarate in neurogenic detrusor overactivity due to spinal cord lesion (SCL) or multiple sclerosis (MS)

Next Previous
X
Search
Trial Profile

Efficacy and safety of fesoterodine fumarate in neurogenic detrusor overactivity due to spinal cord lesion (SCL) or multiple sclerosis (MS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Nov 2021 Results (n=124) assessing the efficacy of fesoterodine fumarate on patients with neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis, published in the Neurourology and Urodynamics.
    • 13 Sep 2021 Primary endpoint (change from baseline to end of treatment in maximum detrusor pressure (Pdetmax) during the filling phase of the UDS and whether the use of Fesoterodine fumarate would decrease it) has been met according to the results presented at the 116th Annual Meeting of the American Urological Association
    • 13 Sep 2021 Results assessing the efficacy of Fesoterodine fumarate on patients with nDO due to Spinal Cord Lesion(SCL) or Multiple sclerosis (MS) presented at the 116th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top